Fassnacht M - Search Results

1

Dendritic cells as potential adjuvant for immunotherapy in adrenocortical carcinoma.

Papewalis C, Fassnacht M, Willenberg HS, Domberg J, Fenk R, Rohr UP, Schinner S, Bornstein SR, Scherbaum WA, Schott M. Papewalis C, et al. Among authors: fassnacht m. Clin Endocrinol (Oxf). 2006 Aug;65(2):215-22. doi: 10.1111/j.1365-2265.2006.02576.x. Clin Endocrinol (Oxf). 2006. PMID: 16886963

2

Angiotensin II type 1 receptor and ACTH receptor expression in human adrenocortical neoplasms.

Schubert B, Fassnacht M, Beuschlein F, Zenkert S, Allolio B, Reincke M. Schubert B, et al. Among authors: fassnacht m. Clin Endocrinol (Oxf). 2001 May;54(5):627-32. doi: 10.1046/j.1365-2265.2001.01253.x. Clin Endocrinol (Oxf). 2001. PMID: 11380493

3

Octreotide LAR treatment throughout pregnancy in an acromegalic woman.

Fassnacht M, Capeller B, Arlt W, Steck T, Allolio B. Fassnacht M, et al. Clin Endocrinol (Oxf). 2001 Sep;55(3):411-5. doi: 10.1046/j.1365-2265.2001.01304.x. Clin Endocrinol (Oxf). 2001. PMID: 11589686 Review.

4

Clodronate inhibits adrenocortical cell proliferation and P450c21 activity.

Fassnacht M, Franke A, Dettling A, Hahner S, Zink M, Wudy S, Allolio B. Fassnacht M, et al. J Endocrinol. 2002 Sep;174(3):509-16. doi: 10.1677/joe.0.1740509. J Endocrinol. 2002. PMID: 12208672

5

N-terminal proopiomelanocortin acts as a mitogen in adrenocortical tumor cells and decreases adrenal steroidogenesis.

Fassnacht M, Hahner S, Hansen IA, Kreutzberger T, Zink M, Adermann K, Jakob F, Troppmair J, Allolio B. Fassnacht M, et al. J Clin Endocrinol Metab. 2003 May;88(5):2171-9. doi: 10.1210/jc.2002-021318. J Clin Endocrinol Metab. 2003. PMID: 12727972

6

Management of adrenocortical carcinoma.

Allolio B, Hahner S, Weismann D, Fassnacht M. Allolio B, et al. Among authors: fassnacht m. Clin Endocrinol (Oxf). 2004 Mar;60(3):273-87. doi: 10.1046/j.1365-2265.2003.01881.x. Clin Endocrinol (Oxf). 2004. PMID: 15008991 Review.

7

AKT is highly phosphorylated in pheochromocytomas but not in benign adrenocortical tumors.

Fassnacht M, Weismann D, Ebert S, Adam P, Zink M, Beuschlein F, Hahner S, Allolio B. Fassnacht M, et al. J Clin Endocrinol Metab. 2005 Jul;90(7):4366-70. doi: 10.1210/jc.2004-2198. Epub 2005 Apr 26. J Clin Endocrinol Metab. 2005. PMID: 15855265

8

Peroxisome proliferator-activated receptor-gamma agonists suppress adrenocortical tumor cell proliferation and induce differentiation.

Betz MJ, Shapiro I, Fassnacht M, Hahner S, Reincke M, Beuschlein F; German and Austrian Adrenal Network. Betz MJ, et al. Among authors: fassnacht m. J Clin Endocrinol Metab. 2005 Jul;90(7):3886-96. doi: 10.1210/jc.2004-1267. Epub 2005 May 10. J Clin Endocrinol Metab. 2005. PMID: 15886257

9

Mitotane for adrenocortical carcinoma treatment.

Hahner S, Fassnacht M. Hahner S, et al. Among authors: fassnacht m. Curr Opin Investig Drugs. 2005 Apr;6(4):386-94. Curr Opin Investig Drugs. 2005. PMID: 15898346 Review.

10

Clinical review: Adrenocortical carcinoma: clinical update.

Allolio B, Fassnacht M. Allolio B, et al. Among authors: fassnacht m. J Clin Endocrinol Metab. 2006 Jun;91(6):2027-37. doi: 10.1210/jc.2005-2639. Epub 2006 Mar 21. J Clin Endocrinol Metab. 2006. PMID: 16551738 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

474 results

Search Page

Filters